-
1
-
-
18444374405
-
Mutations of the BRAF gene in human cancer
-
Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-954.
-
(2002)
Nature
, vol.417
, pp. 949-954
-
-
Davies, H.1
Bignell, G.R.2
Cox, C.3
-
2
-
-
0036894746
-
BRAF and RAS mutations in human lung cancer and melanoma
-
Brose MS, Volpe P, Feldman M et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997-7000.
-
(2002)
Cancer Res
, vol.62
, pp. 6997-7000
-
-
Brose, M.S.1
Volpe, P.2
Feldman, M.3
-
3
-
-
10744222648
-
Mutations of the BRAF gene in benign and malignant melanocytic lesions
-
Yazdi AS, Palmedo G, Flaig MJ et al. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 2003;121:1160-1162.
-
(2003)
J Invest Dermatol
, vol.121
, pp. 1160-1162
-
-
Yazdi, A.S.1
Palmedo, G.2
Flaig, M.J.3
-
4
-
-
79960027865
-
BRAF targeted therapy changes the treatment paradigm in melanoma
-
Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol 2011;8:426-433.
-
(2011)
Nat Rev Clin Oncol
, vol.8
, pp. 426-433
-
-
Ribas, A.1
Flaherty, K.T.2
-
5
-
-
33847220364
-
Melanoma biology and new targeted therapy
-
Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007;445:851-857.
-
(2007)
Nature
, vol.445
, pp. 851-857
-
-
Gray-Schopfer, V.1
Wellbrock, C.2
Marais, R.3
-
6
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364: 2507-2516.
-
(2011)
N Engl J Med
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
-
7
-
-
77956030786
-
Inhibition of mutated, activated BRAF in metastatic melanoma
-
Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-819.
-
(2010)
N Engl J Med
, vol.363
, pp. 809-819
-
-
Flaherty, K.T.1
Puzanov, I.2
Kim, K.B.3
-
8
-
-
84863116743
-
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
-
Sosman JA, Kim KB, Schuchter L et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-714.
-
(2012)
N Engl J Med
, vol.366
, pp. 707-714
-
-
Sosman, J.A.1
Kim, K.B.2
Schuchter, L.3
-
10
-
-
33749018219
-
Mechanisms of cutaneous toxicities to EGFR inhibitors
-
Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6: 803-812.
-
(2006)
Nat Rev Cancer
, vol.6
, pp. 803-812
-
-
Lacouture, M.E.1
-
11
-
-
56449119043
-
Keratosis pilaris: A follicular hyperkeratosis
-
Hwang S, Schwartz RA. Keratosis pilaris: A follicular hyperkeratosis. Cutis 2008;82: 177-180.
-
(2008)
Cutis
, vol.82
, pp. 177-180
-
-
Hwang, S.1
Schwartz, R.A.2
-
12
-
-
84856582443
-
Ultraviolet A and photosensitivity during vemurafenib therap
-
Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 2012;366:480-481.
-
(2012)
N Engl J Me
, vol.366
, pp. 480-481
-
-
Dummer, R.1
Rinderknecht, J.2
Goldinger, S.M.3
-
13
-
-
80054044954
-
Vemurafenib in melanoma with BRAF V600E mutation
-
Dalle S, Poulalhon N, Thomas L. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;365:1448-1449.
-
(2011)
N Engl J Med
, vol.365
, pp. 1448-1449
-
-
Dalle, S.1
Poulalhon, N.2
Thomas, L.3
-
14
-
-
84858729203
-
Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management
-
Zimmer L, Livingstone E, Hillen U et al. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol 2012;148:357-361.
-
(2012)
Arch Dermatol
, vol.148
, pp. 357-361
-
-
Zimmer, L.1
Livingstone, E.2
Hillen, U.3
-
15
-
-
84863463901
-
Atypical melanocytic proliferations and new primary melanomas in advanced melanoma patients undergoing selective BRAF inhibition
-
Zimmer L, Hillen U, Livingstone E et al. Atypical melanocytic proliferations and new primary melanomas in advanced melanoma patients undergoing selective BRAF inhibition. J Clin Oncol 2012;30: 2375-2383.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2375-2383
-
-
Zimmer, L.1
Hillen, U.2
Livingstone, E.3
-
17
-
-
41149092411
-
Keratoacanthoma and infundibulocystic squamous cell carcinoma
-
Kossard S, Tan KB, Choy C. Keratoacanthoma and infundibulocystic squamous cell carcinoma. Am J Dermatopathol 2008;30:127-134.
-
(2008)
Am J Dermatopathol
, vol.30
, pp. 127-134
-
-
Kossard, S.1
Tan, K.B.2
Choy, C.3
-
18
-
-
77953590523
-
Keratoacanthoma: Facts and controversies
-
Ko CJ. Keratoacanthoma: Facts and controversies. Clin Dermatol 2010;28:254-261.
-
(2010)
Clin Dermatol
, vol.28
, pp. 254-261
-
-
Ko, C.J.1
-
19
-
-
33845705260
-
Keratoacanthomas associated with sorafenib therapy
-
Kong HH, Cowen EW, Azad NS et al. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 2007;56:171-172.
-
(2007)
J Am Acad Dermatol
, vol.56
, pp. 171-172
-
-
Kong, H.H.1
Cowen, E.W.2
Azad, N.S.3
-
20
-
-
68949094219
-
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib
-
Arnault JP, Wechsler J, Escudier B et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009;27: e59-e61.
-
(2009)
J Clin Oncol
, vol.27
-
-
Arnault, J.P.1
Wechsler, J.2
Escudier, B.3
-
21
-
-
65249127575
-
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib
-
Dubauskas Z, Kunishige J, Prieto VG et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 2009;7:20-23.
-
(2009)
Clin Genitourin Cancer
, vol.7
, pp. 20-23
-
-
Dubauskas, Z.1
Kunishige, J.2
Prieto, V.G.3
-
22
-
-
84855435059
-
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1
-
Arnault JP, Mateus C, Escudier B et al. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res 2012;18: 263-272.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 263-272
-
-
Arnault, J.P.1
Mateus, C.2
Escudier, B.3
-
23
-
-
77957350123
-
Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors
-
Kefford R, Arkenau H, Brown MP et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010;28(suppl 15):8503.
-
(2010)
J Clin Oncol
, vol.28
, Issue.SUPPL. 15
, pp. 8503
-
-
Kefford, R.1
Arkenau, H.2
Brown, M.P.3
-
25
-
-
84864285704
-
Dabrafenib in BRAF-mutated metastatic melanoma: A multicenter, open-label, phase 3 randomised controlled trial
-
Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicenter, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-365.
-
(2012)
Lancet
, vol.380
, pp. 358-365
-
-
Hauschild, A.1
Grob, J.J.2
Demidov, L.V.3
-
26
-
-
79951498422
-
PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial
-
Lacouture ME, McArthur GA, Chapman PB et al. PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial. J Clin Oncol 2010;28(suppl 15):8592.
-
(2010)
J Clin Oncol
, vol.28
, Issue.SUPPL. 15
, pp. 8592
-
-
Lacouture, M.E.1
McArthur, G.A.2
Chapman, P.B.3
-
27
-
-
0024413216
-
Oncogene activation in human benign tumors of the skin (keratoacanthomas): Is HRAS involved in differentiation as well as proliferation?
-
Corominas M, Kamino H, Leon J et al. Oncogene activation in human benign tumors of the skin (keratoacanthomas): Is HRAS involved in differentiation as well as proliferation? Proc Natl Acad Sci U S A 1989;86:6372-6376.
-
(1989)
Proc Natl Acad Sci U S A
, vol.86
, pp. 6372-6376
-
-
Corominas, M.1
Kamino, H.2
Leon, J.3
-
28
-
-
84862908526
-
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors
-
Oberholzer PA, Kee D, Dziunycz P et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012;30:316-321.
-
(2012)
J Clin Oncol
, vol.30
, pp. 316-321
-
-
Oberholzer, P.A.1
Kee, D.2
Dziunycz, P.3
-
29
-
-
84862908097
-
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors
-
Su F, Viros A, Milagre C et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366:207-215.
-
(2012)
N Engl J Med
, vol.366
, pp. 207-215
-
-
Su, F.1
Viros, A.2
Milagre, C.3
-
30
-
-
77949732073
-
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
-
Poulikakos PI, Zhang C, Bollag G et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464:427-430.
-
(2010)
Nature
, vol.464
, pp. 427-430
-
-
Poulikakos, P.I.1
Zhang, C.2
Bollag, G.3
-
31
-
-
68949097283
-
Viral-associated nonmelanoma skin cancers: A review
-
Dubina M, Goldenberg G. Viral-associated nonmelanoma skin cancers: A review. Am J Dermatopathol 2009;31:561-573.
-
(2009)
Am J Dermatopathol
, vol.31
, pp. 561-573
-
-
Dubina, M.1
Goldenberg, G.2
-
32
-
-
84868193136
-
Cutaneous manifestations of dabrafenib (GSK2118436): A selective inhibitor of mutant BRAF in patients with metastatic melanoma
-
Anforth RM, Blumetti TC, Kefford RF et al. Cutaneous manifestations of dabrafenib (GSK2118436): A selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol 2012;167: 1153-1160.
-
(2012)
Br J Dermatol
, vol.167
, pp. 1153-1160
-
-
Anforth, R.M.1
Blumetti, T.C.2
Kefford, R.F.3
-
33
-
-
84863376176
-
Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma
-
Alloo A, Garibyan L, LeBoeuf N et al. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. Arch Dermatol 2012;148: 363-366.
-
(2012)
Arch Dermatol
, vol.148
, pp. 363-366
-
-
Alloo, A.1
Garibyan, L.2
Leboeuf, N.3
-
34
-
-
84864021610
-
Systemic retanoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib
-
Anforth R, Bluemetti TC, Mohd Affandi A et al. Systemic retanoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib. J Clin Oncol 2012;30: e165-e167.
-
(2012)
J Clin Oncol
, vol.30
-
-
Anforth, R.1
Bluemetti, T.C.2
Mohd Affandi, A.3
-
35
-
-
84872679025
-
Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0
-
Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol 2012; 67:1025-1039.
-
(2012)
J Am Acad Dermatol
, vol.67
, pp. 1025-1039
-
-
Chen, A.P.1
Setser, A.2
Anadkat, M.J.3
|